Hüseyin Akıllı

9PUBLICATIONS
15CO-AUTHORS
Predictive and prognostic markersObstetrics and gynaecologyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Oct 17, 2025
Timing and survival benefits of cytoreduction in patients with recurrent leiomyosarcoma.

Mehmet Tunç, Hüseyin Akıllı, Esra Kuşçu

|Oct 15, 2025
Fertility sparing surgery for malignant ovarian sex-cord stromal tumors: long-term obstetric and oncologic outcomes.

Mehmet Tunç, Hüseyin Akıllı, Asuman Nihan Haberal Reyhan

|Jun 05, 2024
Impact of adjuvant treatments and risk factors on survival in 2023 FIGO stage IIB endometrial cancer patients: Turkish Gynecologic Oncology Group Study.

Utku Akgör, Derman Basaran, Mehmet Mutlu Meydanli

|Sep 22, 2023
Fertility-sparing approach to malignant ovarian germ cell tumors - Oncologic and obstetric outocome: A retrospective study.

Ali Ayhan, Mehmet Tunç, Hüseyin Akıllı

|Oct 20, 2022
Hyperthermic intraperitoneal chemotherapy in the treatment of recurrent ovarian cancer: When, and for whom?

Ali Ayhan, Huseyin Akilli, Mehmet Ali Abasiyanik

|Mar 09, 2022
Survival in recurrent ovarian cancer patients before and after the bevacizumab era: an observational single-centre study.

Huseyin Akilli, Samed Rahatli, Khayala Aliyeva

Pageof 2